Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation
JACC: Clinical Electrophysiology · 2024-05 · 10 (5) · 930-940
DOI: 10.1016/j.jacep.2024.01.020 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2024-05. Verfasst von Jonathan P Piccini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrophysiology, Duke Clinical Research Institute/Duke University Medical Center, Durham, North Carolina, USA. Electronic address: jo…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Botulinum Toxins, Type A, Postoperative Complications. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: AbbVie Inc, Food Allergy and Anaphylaxis Network.
Abstract (Originalsprache)
BACKGROUND: Postoperative atrial fibrillation (POAF) is associated with increased morbidity and mortality. Epicardial injection of botulinum toxin may suppress POAF. OBJECTIVES: This study sought to assess the safety and efficacy of AGN-151607 for the prevention of POAF after cardiac surgery. METHODS: This phase 2, randomized, placebo-controlled trial assessed the safety and efficacy of AGN-151607, 125 U and 250 U vs placebo (1:1:1), for the prevention of POAF after cardiac surgery. Randomization was stratified by age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Electrophysiology, Duke Clinical Research Institute/Duke University Medical Center, Durham, North Carolina, USA. Electronic address: jonathan.piccini@duke.edu.
- Cardiovascular Division, Karolinska Institute, Stockholm, Sweden.
- Division of Cardiology, St Michael's Hospital, Toronto, Ontario, Canada.
- Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
- Division of Cardiovascular Research, Lankenau Heart Institute, Wynnewood, Pennsylvania, USA.
- Department of Thoracic Surgery, Baylor Scott and White Health, Dallas, Texas, USA.
Förderung
- AbbVie Inc
- Food Allergy and Anaphylaxis Network
Zitieren
APA
Piccini, J. P., Ahlsson, A., Dorian, P., Gillinov, A. M., Kowey, P. R., Mack, M. J., Milano, C. A., Noiseux, N., Perrault, L. P., Ryan, W., Steinberg, J. S., Voisine, P., Waldron, N. H., Gleason, K. J., Titanji, W., Leaback, R. D., O'Sullivan, A., Ferguson, W. G., Benussi, S., & NOVA-AF Investigators (2024). Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation. JACC: Clinical Electrophysiology, 10(5), 930-940. https://doi.org/10.1016/j.jacep.2024.01.020
Vancouver
Piccini JP, Ahlsson A, Dorian P, Gillinov AM, Kowey PR, Mack MJ, et al. Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation. JACC: Clinical Electrophysiology. 2024;10(5):930-940. doi:10.1016/j.jacep.2024.01.020
BibTeX
@article{Piccini2024,
author = {Piccini, Jonathan P and Ahlsson, Anders and Dorian, Paul and Gillinov, A Marc and Kowey, Peter R and Mack, Michael J and Milano, Carmelo A and Noiseux, Nicolas and Perrault, Louis P and Ryan, William and Steinberg, Jonathan S and Voisine, Pierre and Waldron, Nathan H and Gleason, Kevin J and Titanji, Wilson and Leaback, Richard D and O'Sullivan, Alexandra and Ferguson, William G and Benussi, Stefano and NOVA-AF Investigators, NOVA-AF Investigators},
title = {Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation},
journal = {JACC: Clinical Electrophysiology},
year = {2024},
volume = {10},
number = {5},
pages = {930--940},
doi = {10.1016/j.jacep.2024.01.020}
}
EUVIMED